Cancer clinical trials in the region Île-de-France

735 currently recruiting clinical trials
Region Île-de-France

Phase 3 Endometrial cancer #NCT06952504 #2024-519331-42-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ...
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MSS/pMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
MSI/dMMR
Excluded previous treatments at localized stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
10 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06824467 #2023-508015-23-00
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required platino resistance
Recurrence 6 months or more after platinum treatme...
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Lung cancer #NCT07472517
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
5 recruiting sites
Boehringer Ingelheim
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07218380 #2025-522855-25-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
FGFR
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Eli Lilly et compagnie
Phase 3 Lung cancer #NCT07361497 #2025-523576-23-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC Non-squamous NSCLC
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
Excluded genetic anomalies
ALK EGFR
8 recruiting sites
Bristol-Myers Squibb
Phase 3 Brain tumors / Central nervous system tumors #NCT05902169 #2023-505829-14-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery Immunotherapy Chemotherapy Radiotherapy
Excluded genetic anomalies
BRAF IDH1/2 NTRK-1/2/3
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
CarThera
Phase 3 Ovarian / Fallopian tubes / Peritoneum cancer #NCT06476184 #2023-508260-30-01
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required histologic sub types
Serous high grade carcinoma (HGSOC) Endometrioid carcinoma Other epithelial ovarian cancer
Required FIGO stages
Stage III Stage IV
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
36 recruiting sites
ARCAGY/ GINECO GROUP
Phase 3 Colon cancer Rectal cancer Pancreas cancer Stomach and esophageal cancer #NCT06937905
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
42 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Lung cancer #NCT06937905
Required histologic types
Neuroendocrine tumor/carcinoma other than SCLC
Required histologic sub types
Neuroendocrine tumor/carcinoid
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
42 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Prostate cancer #NCT07225946 #2025-522713-29-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
8 recruiting sites
Janssen